Page 106 - 51 the significance--29.2_opt

72. Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel
strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract
2008;14(6):782-90.
73. Bailey CJ, Day C. SGLT2 inhibitors: glucuretic treatment for type 2 diabetes British
Journal of Diabetes & Vascular Disease 2010;10:193-199.
74. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients
with type 2 diabetes who have inadequate glycaemic control with metformin:
a randomised, double-blind, placebo-controlled trial. Lancet 2010;375(9733):
2223-33.
75. NHS - UK Medicines Information. Canagliflozin 2010.
76. Harno E, White A. Will treating diabetes with 11beta-HSD1 inhibitors affect the HPA
axis? Trends Endocrinol Metab 2010;21(10):619-27.
77. Qureshi SA, Rios Candelore M, Xie D, Yang X, Tota LM, Ding VD, et al. A novel
glucagon receptor antagonist inhibits glucagon-mediated biological effects.
Diabetes 2004;53(12):3267-73.
78. Rivera N, Everett-Grueter CA, Edgerton DS, Rodewald T, Neal DW, Nishimura E, et al.
A novel glucagon receptor antagonist, NNC 25-0926, blunts hepatic glucose pro-
duction in the conscious dog. J Pharmacol Exp Ther 2007;321(2):743-52.
79. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, et al. Interleukin-1-
receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356(15):1517-26.
80. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al.
Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in
human pancreatic islets. J Clin Invest 2002;110(6):851-60.
81. WHO. Diabetes Factsheet 312: WHO, 2009.
82. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS, et al. Cardiovascular
outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med
2008;168(19):2070-80.
83. Lavernia F, Largay J, Ridge T. Incretin-related therapies: Targeting the underlying
physiology and cardiometabolic factors of type 2 diabetes. The Journal of Family
Practice 2009;58 (No 2 Suppl).
84. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in
type 2 diabetic patients with inadequate glycemic control by diet and exercise:
a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010;
33(10):2217-24.
85. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition
with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32(4):650-7.
86. Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat
Rev Drug Discov 2010;9(7):551-9.
87. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of
metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes
mellitus: a systematic review. J Intern Med 2004;256(1):1-14.
88. Matikainen N, Manttari S, Schweizer A, Ulvestad A, Mills D, Dunning BE, et al. Vilda-
gliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles
in patients with type 2 diabetes. Diabetologia 2006;49(9):2049-57.
89. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of
metformin are at low risk of incident cancer: a cohort study among people with
type 2 diabetes. Diabetes Care 2009;32(9):1620-5.
90. Garmendia ML, Pereira A, Alvarado ME, Atalah E. Relation between insulin resist-
ance and breast cancer among Chilean women. Ann Epidemiol 2007;17(6):403-9.
91. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer-related
mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes
Care 2006;29(2):254-8.
92. Derosa G, Sibilla S. Optimizing combination treatment in the management of type
2 diabetes. Vasc Health Risk Manag 2007;3(5):665-71.
93. Brunton S. Beyond glycemic control: treating the entire type 2 diabetes disorder.
Postgrad Med 2009;121(5):68-81.
94. Stolar MW, Hoogwerf BJ, Gorshow SM, Boyle PJ, Wales DO. Managing type 2 diabetes:
going beyond glycemic control. J Manag Care Pharm 2008;14(5 Suppl B):s2-19.
95. Ling C, Groop L. Epigenetics: a molecular link between environmental factors and
type 2 diabetes. Diabetes 2009;58(12):2718-25.

106